Biotech Values

[zipjet]

The willingness of non-government third-party payers to pay for Provenge might not be as inelastic as you think.

It might not.

But as you know, you can measure the elasticity on both sides of current pricing. I would be very surprised if price cuts produced higher revenue, and shocked if it produced higher profits.

In contrast, higher* pricing is likely to generate higher revenue and profits.

ij

* No doubt, and to your point, at some increase the demand could turn elastic - resulting in lower revenues.